Tarlatamab Shows Promise in Tackling Previously Treated SCLC
Pediatric News ,
The investigational bispecific T-cell engager tarlatamab achieved durable responses and clinically meaningful survival outcomes…
Tarlatamab Shows Promise in Tackling Previously Treated SCLC
Medscape,
The investigational bispecific T-cell engager tarlatamab achieved durable responses and clinically meaningful survival outcomes…
FDA Grants Priority Review to Tarlatamab for Small Cell Lung Cancer
OncLive,
The FDA has accepted and granted priority review to the biologics license application (BLA) seeking the approval of tarlatamab…
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond
MedPage Today,
Meeting Coverage > ESMO Tarlatamab achieves 40% overall response rate at the dose selected for continued evaluation by Charles…